NVO, CFN, SNY And BSX, Pushing Health Care Sector Downward

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 76 points (0.5%) at 15,300 as of Tuesday, July 9, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 2,101 issues advancing vs. 849 declining with 106 unchanged.

The Health Care sector currently sits down 0.3% versus the S&P 500, which is up 1.2%. On the negative front, top decliners within the sector include Intuitive Surgical ( ISRG), down 17.9%, Quest Diagnostics ( DGX), down 5.2%, Laboratory Corporation of America Holdings ( LH), down 4.3% and Abbott Laboratories ( ABT), down 0.9%. Top gainers within the sector include Regeneron Pharmaceuticals ( REGN), up 2.1%, Celgene Corporation ( CELG), up 1.9%, WellPoint ( WLP), up 1.6%, Cigna ( CI), up 1.5% and Alexion Pharmaceuticals ( ALXN), up 1.5%.

TheStreet would like to highlight 4 stocks pushing the sector lower today:

4. Novo Nordisk A/S ( NVO) is one of the companies pushing the Health Care sector lower today. As of noon trading, Novo Nordisk A/S is down $2.04 (-1.3%) to $158.71 on light volume. Thus far, 92,050 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 300,200 shares. The stock has ranged in price between $158.17-$160.19 after having opened the day at $159.22 as compared to the previous trading day's close of $160.75.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $88.0 billion and is part of the drugs industry. Shares are down 1.5% year to date as of the close of trading on Monday. Currently there is 1 analyst that rates Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, CareFusion ( CFN) is down $1.08 (-2.8%) to $37.16 on average volume. Thus far, 1.4 million shares of CareFusion exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $37.13-$38.33 after having opened the day at $38.24 as compared to the previous trading day's close of $38.24.

CareFusion Corporation provides various healthcare products and services in the United States and internationally. It operates in two segments, Medical Systems and Procedural Solutions. CareFusion has a market cap of $8.3 billion and is part of the health services industry. Shares are up 33.8% year to date as of the close of trading on Monday. Currently there are 7 analysts that rate CareFusion a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates CareFusion as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full CareFusion Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Sanofi ( SNY) is down $0.32 (-0.6%) to $51.36 on light volume. Thus far, 522,711 shares of Sanofi exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $51.22-$51.89 after having opened the day at $51.82 as compared to the previous trading day's close of $51.68.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $137.0 billion and is part of the drugs industry. Shares are up 9.1% year to date as of the close of trading on Monday. Currently there are 6 analysts that rate Sanofi a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Boston Scientific ( BSX) is down $0.19 (-2.0%) to $9.18 on average volume. Thus far, 10.7 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 18.7 million shares. The stock has ranged in price between $9.16-$9.36 after having opened the day at $9.32 as compared to the previous trading day's close of $9.37.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific has a market cap of $12.5 billion and is part of the health services industry. Shares are up 63.5% year to date as of the close of trading on Monday. Currently there are 5 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 14 rate it a hold.

TheStreet Ratings rates Boston Scientific as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Boston Scientific Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).
null